SR
Shraddha Rastogi
National Institutes of Health
Research areas: Medicine · Oncology · Cancer Immunotherapy and Biomarkers · Occupational exposure and asthma · Occupational and environmental lung diseases
0000-0003-0680-0407
Employment
-
National Institutes of Health Post Doc Fellow
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (22)
- Data from SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST) Save
- SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST) Save
- Supplementary Figure S1 from SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST) Save
- Supplementary Figure S2 from SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST) Save
- Supplementary Figure S3 from SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST) Save
- Supplementary Table S1 from SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST) Save
- Supplementary Table S2 from SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST) Save
- Supplementary Table S3 from SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST) Save
- Topoisomerase IIIb protects from immune dysregulation and tumorigenesis Save
- A Phase II Pilot Study of Anti‐PD‐L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation Save
- Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors Save
- An update on the status of HSP90 inhibitors in cancer clinical trials Save
- Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers Save
- The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial Save
- A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma Save
- Seasonal plasticity in immunocompetent cytokines (IL-2, IL-6, and TNF-α), myeloid progenitor cell (CFU-GM) proliferation, and LPS-induced oxido-inflammatory aberrations in a tropical rodent Funambulus pennanti: role of melatonin Save
- Analysis of systemic immune changes in patients with advanced cancer treated with immunotoxin LMB-100 and tofacitinib. Save
- Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreatobiliary cancer. Save
- Role of melatonin and HSF-1\HSP-70 in modulating cold stress-induced immunosuppression in a tropical rodent- Funambulus pennanti [Volume 87, January 2020, 102456] Save
- Nephroprotective effect of melatonin and L-Ascorbic acid (Vitamin-C) against ampicillin- induced toxicity in Funambulus pennanti Save